Tag Archives: propensity score matching

Introduction Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, was first used as a type 2 diabetes drug. However, in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial, dapagliflozin effectively reduced both hospitalisations due to heart failure (HF) and death in patients with HF with reduced ejection fraction (HFrEF).1 Therefore, the European Society of Cardiology (ESC) and Japanese Circulation Society (JCS) guidelines recommended the administration of SGLT2 inhibitors to patients with HFrEF.2,3 Moreover, dapagliflozin suppressed both renal failure exacerbation and all-cause death in patie